News

AliveDx Suisse S.A. and Medical Development Medical Devices WLL have signed a distribution agreement, which will enable Medical Development Medical Devices to distribute the MosaiQ® solution in the Kingdom of Bahrain. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions. This strategic collaboration with a solid…

AliveDx Suisse S.A. and Lavichem Joint Stock Company have signed a distribution agreement, which will enable Lavichem to distribute the MosaiQ® solution in North Vietnam. The distribution agreement takes effect immediately. AliveDx is committed to broadening its reach and presence across different regions, aiming to generate both clinical and economical value for clinicians, helping them…

AliveDx Suisse S.A. and Medlinks Consulting Joint Stock Company have signed a distribution agreement, which will enable Medlinks to distribute the MosaiQ® solution in South Vietnam. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions and to creating clinical and economical value for clinicians, helping them…

We are excited to announce that our abstract titled “Performance characteristics of a novel, fully automated immunoassay microarray for the qualitative serological detection of specific IgE directed against Bet v 1” has been accepted by the European Congress of Immunology (ECI 2024), a major international event on immunology, to be held in Dublin, Ireland, from…

AliveDx Suisse S.A. and Patho Solutions Malaysia Sdn. Bhd. have signed a distribution agreement, which will enable Patho Solutions Malaysia to distribute the MosaiQ® solution in Malaysia. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions and to creating clinical and economical value for clinicians, helping…

AliveDx Suisse S.A. and Everlight Biotech Co. Ltd. have signed a distribution agreement, which will enable Everlight Biotech Co. Ltd. to distribute the MosaiQ® solution in Taiwan. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions. This strategic collaboration with a prominent partner in Taiwan underscores…

At AliveDx, we understand that the success of our business is closely linked to the wellbeing of the communities in which we operate. Our goal is to advance sustainable practices in every aspect of our operations. We are pleased to present the AliveDx 2023 Sustainability Report as a testament to our dedication. The 2023 Sustainability…

AliveDx Suisse S.A. and Ozgun Kimya A.S. have signed a distribution agreement, which will enable Ozgun Kimya A.S. to distribute the MosaiQ® solution in Türkiye. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s consistent commitment to grow and expand its geographical presence. It will enable both parties to introduce new quality services…

We are excited to announce that our recently CE-marked MosaiQ® AiPlex CTD microarray immunoassay, which aims to shorten time-to-diagnosis for autoimmune patients, is now available in over 35 markets across Europe and the Asia Pacific region. The MosaiQ AiPlex CTD solution is designed to aid in the diagnosis of multiple Connective Tissue Diseases, including Systemic…

Our leadership team recently gathered to celebrate 2023 achievements and kick off the new year. As part of a highly energizing team-building activity, and to bring our environmental, social and governance commitments to life, the team built solar lamps that will be donated to children in energy-poor countries. Ensuring universal access to affordable and clean…